<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542944</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-11-9090-AN-CTIL</org_study_id>
    <nct_id>NCT01542944</nct_id>
  </id_info>
  <brief_title>TevaGastrim for Stem Cell Mobilization Sibling Donors</brief_title>
  <official_title>TevaGastrim for Stem Cell Mobilization of HLA Matched Sibling Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of TevaGastrim which is a biosimilar
      version of Filgrastim recombinant human G-CSF (G-CSF) in mobilizing sufficient number of stem
      cells from normal sibling donors for allogeneic stem cell transplantation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mobilisation success rate</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mobilisation success rate is defined as the mobilisation of a PBSC graft containing &gt;2x106 CD34+ cells/kg in ≤ 4 apheresis sessions. We will evaluate the time from chemotherapy to stem cell collection,number of collections required to reach &gt;2x106 CD34+ cells/kg, number of CD34+ cells collected and percentage of patients reaching &gt;5x10 CD34+ cells/kg in ≤ 4 apheresis sessions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>engraftment after transplantation</measure>
    <time_frame>100 days</time_frame>
    <description>speed of engraftment is determined by the time until recovery of blood counts after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor safety</measure>
    <time_frame>100 days</time_frame>
    <description>To determine side effects to the stem cell donor</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <arm_group>
    <arm_group_label>TevaGastrim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>treatment with TevaGastrim for allogeneic stem cell collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TevaGastrim</intervention_name>
    <description>TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.</description>
    <arm_group_label>TevaGastrim</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between 18 and 70 years.

          2. Normal sibling donor that is HLA matched to a patient with AML or MDS that needs and
             is eligible for allogeneic stem cell transplantation

          3. Written informed consent.

        Exclusion Criteria:

          1. Inability to tolerate PBPC harvest.

          2. Peripheral venous access not possible.

          3. Positive pregnancy test for female donors.

          4. Positive serology for hepatitis C and/or HBSAg, unless negative for antigen PCR.

          5. Psychiatric, addictive, or any disorder which compromises ability to give truly
             informed consent for participation in this study.

          6. Treatment with other investigational drugs.

          7. Known sensitivity to CHO derived products.

          8. HIV positive.

          9. History of malignant disease or current malignancy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arnon Nagler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chaim Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Tel-Hashomer</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 19, 2012</study_first_submitted>
  <study_first_submitted_qc>March 1, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute myeloid leukemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>Stem Cell Mobilization</keyword>
  <keyword>Allogeneic Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

